News · eGov
Biodeal Pharmaceuticals outlines its strategy for sterile injectables, R&D expansion and regulatory readiness after a year marked by a Rs 385 crore investment and a major facility acquisition.
✦ AI SUMMARY 30-second read
- Biodeal received a strategic investment of Rs 385 crore from RMB Capitalworks in 2026.
- The company acquired Biological E's sterile injectable facility at Paonta Sahib, Himachal Pradesh, with an annual capacity of approximately 135 million units.
- Revenue growth has exceeded 40 per cent for more than three consecutive years.
Why it matters: Biodeal's moves signal a broader shift in Indian CDMO ambition from cost-competitive manufacturing toward technically complex, globally compliant drug production.
This summary was generated by AI. Editors may review and update it.
Biodeal Pharmaceuticals has described 2026 as a defining year, citing a Rs 385 crore strategic investment from RMB Capitalworks and the acquisition of a sterile injectable manufacturing facility in Paonta Sahib, Himachal Pradesh, as the two developments most likely to shape its trajectory in the years ahead.
The company also completed the full redemption of a Rs 110 crore investment by Piramal Alternatives, delivering an internal rate of return of over 20 per cent. Biodeal said it has sustained revenue growth of over 40 per cent for more than three consecutive years.
What was announced
The Paonta Sahib facility, acquired from Biological E, has an annual capacity of approximately 135 million units. Biodeal said its Carbapenem line at the site is now operational and validated under its ownership.
For 2027, the company plans to expand the facility's output beyond Carbapenems into products such as FCM and Heparin, and to build capabilities in pre-filled syringe and lyophilised formats. Work on an R&D innovation centre is also under way to support product development in more differentiated, technically complex formulations.
Regulatory readiness is a stated priority, with the company citing a pathway towards PIC/S and EU standards as part of its operational planning.
Strategic direction
Biodeal said the move into sterile injectables complements rather than replaces its existing strengths. The company stated it has more than two decades of experience in nasal drug delivery and specialty formulations.
Company leadership described the expansion as deliberate, cautioning against diversification for its own sake. The view expressed is that Indian contract development and manufacturing organisations have an opportunity to move beyond cost-competitive positioning and become strategic contributors to global supply chains.
Trust, consistent quality and technical problem-solving were identified as the factors most likely to determine which CDMOs build lasting international relationships.
Sector outlook
On broader industry trends, Biodeal noted growing customer demand for differentiated formulations and specialised manufacturing, including sterile injectables, nasal sprays and inhalation products. Supply reliability and the ability to meet multi-market regulatory expectations were cited as areas of increasing customer scrutiny.
The company said building such capabilities requires time, capital and specialist talent, and that investment in facilities, validation and regulatory systems is typically needed before a programme can scale commercially.
On government support, Biodeal called for sustained backing for research and development, particularly for smaller companies, alongside investment in scientific education, shared analytical infrastructure and a predictable regulatory environment with transparent, timely review processes.